Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism

Thromb Res. 2020 Aug:192:113-115. doi: 10.1016/j.thromres.2020.05.017. Epub 2020 May 15.

¹ Venous Thromboembolism Unit, Internal Medicine. Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Medicine, School of Medicine. Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain.
² Venous Thromboembolism Unit, Internal Medicine. Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Medicine, School of Medicine. Universidad Complutense de Madrid, Spain.
³ Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
⁴ Venous Thromboembolism Unit, Internal Medicine. Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Medicine, School of Medicine. Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain. Electronic address: pbdemelo@hotmail.com.

Abstract

•
COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.
•
Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.
•
Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.